Gene info: ID 1548

Gene: CYP2A6

GENE ID: 1548

Description: cytochrome P450 family 2 subfamily A member 6

Gene type: protein-coding

Location: 19q13.2

dbXrefs: Ensembl:ENSG00000255974 MIM:122720 Vega:OTTHUMG00000182713 UniprotKB:P11509

RefSeq: NG_008377.1

Retrived from: PubMed|SNP Mapped

SNPs: 2 ANCO-SNPs

Phenotype: ND|AD

# Publications: 235

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 2.543e-1 (AD) 6.361e-5 (ND)

ANCO-SNPs

SNP ID	Position	Alleles	Trait	Variation Type
rs56256500	chr19:40848266 (GRCh38.p7)	G>A / G>C / G>T	nicotine dependence	SNV(Single Nucleotide Variation)
rs56113850	chr19:40847202 (GRCh38.p7)	T>C	nicotine dependence	SNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
BTBD18	0.515
RNF222	0.492
MEOX1	0.491
CDHR5	0.486
B3GNT6	0.484
SPDYE1	0.482
TBC1D29	0.48
SPDYE2	0.48
SLCO1B1	0.475
OR10K1	0.475

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
TNFRSF11B	-0.259
ZSCAN5B	-0.255
IL17C	-0.253
FOXJ1	-0.251
CARD18	-0.25
VSIG4	-0.25
C4orf47	-0.249
OXTR	-0.247
NMI	-0.245
NAT2	-0.245

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB04665	Coumarin	Small Molecule	91-64-5	Experimental	Target
DB07609	N,N-DIMETHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE	Small Molecule		Experimental	Target
DB07617	N-METHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE	Small Molecule		Experimental	Target
DB07621	(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE	Small Molecule		Experimental	Target
DB07623	4,4'-DIPYRIDYL DISULFIDE	Small Molecule		Experimental	Target
DB00170	Menadione	Small Molecule	58-27-5	Approved\|Nutraceutical	Enzyme
DB00182	Amphetamine	Small Molecule	300-62-9	Approved\|Illicit\|Investigational	Enzyme
DB00184	Nicotine	Small Molecule	54-11-5	Approved	Enzyme
DB00207	Azithromycin	Small Molecule	83905-01-5	Approved	Enzyme
DB00216	Eletriptan	Small Molecule	143322-58-1	Approved\|Investigational	Enzyme
DB00238	Nevirapine	Small Molecule	129618-40-2	Approved	Enzyme
DB00255	Diethylstilbestrol	Small Molecule	56-53-1	Approved\|Investigational	Enzyme
DB00257	Clotrimazole	Small Molecule	23593-75-1	Approved	Enzyme
DB00281	Lidocaine	Small Molecule	137-58-6	Approved	Enzyme
DB00312	Pentobarbital	Small Molecule	76-74-4	Approved\|Investigational	Enzyme
DB00313	Valproic Acid	Small Molecule	99-66-1	Approved\|Investigational	Enzyme
DB00316	Acetaminophen	Small Molecule	103-90-2	Approved	Enzyme
DB00356	Chlorzoxazone	Small Molecule	95-25-0	Approved	Enzyme
DB00363	Clozapine	Small Molecule	5786-21-0	Approved	Enzyme
DB00381	Amlodipine	Small Molecule	88150-42-9	Approved	Enzyme
DB00396	Progesterone	Small Molecule	57-83-0	Approved	Enzyme
DB00412	Rosiglitazone	Small Molecule	122320-73-4	Approved\|Investigational	Enzyme
DB00470	Dronabinol	Small Molecule	1972-08-3	Approved\|Illicit	Enzyme
DB00471	Montelukast	Small Molecule	158966-92-8	Approved	Enzyme
DB00495	Zidovudine	Small Molecule	30516-87-1	Approved	Enzyme
DB00531	Cyclophosphamide	Small Molecule	50-18-0	Approved\|Investigational	Enzyme
DB00544	Fluorouracil	Small Molecule	51-21-8	Approved	Enzyme
DB00553	Methoxsalen	Small Molecule	298-81-7	Approved	Enzyme
DB00568	Cinnarizine	Small Molecule	298-57-7	Approved\|Investigational	Enzyme
DB00604	Cisapride	Small Molecule	81098-60-4	Approved\|Investigational\|Withdrawn	Enzyme
DB00636	Clofibrate	Small Molecule	637-07-0	Approved\|Investigational	Enzyme
DB00675	Tamoxifen	Small Molecule	10540-29-1	Approved	Enzyme
DB00690	Flurazepam	Small Molecule	17617-23-1	Approved\|Illicit\|Investigational	Enzyme
DB00752	Tranylcypromine	Small Molecule	155-09-9	Approved\|Investigational	Enzyme
DB00755	Tretinoin	Small Molecule	302-79-4	Approved\|Investigational\|Nutraceutical	Enzyme
DB00763	Methimazole	Small Molecule	60-56-0	Approved	Enzyme
DB00818	Propofol	Small Molecule	2078-54-8	Approved\|Investigational	Enzyme
DB00860	Prednisolone	Small Molecule	50-24-8	Approved	Enzyme
DB00882	Clomifene	Small Molecule	911-45-5	Approved\|Investigational	Enzyme
DB00921	Buprenorphine	Small Molecule	52485-79-7	Approved\|Illicit\|Investigational	Enzyme
DB00951	Isoniazid	Small Molecule	54-85-3	Approved\|Investigational	Enzyme
DB00972	Azelastine	Small Molecule	58581-89-8	Approved	Enzyme
DB00983	Formoterol	Small Molecule	73573-87-2	Approved\|Investigational	Enzyme
DB01006	Letrozole	Small Molecule	112809-51-5	Approved\|Investigational	Enzyme
DB01011	Metyrapone	Small Molecule	54-36-4	Approved\|Investigational	Enzyme
DB01026	Ketoconazole	Small Molecule	65277-42-1	Approved\|Investigational	Enzyme
DB01028	Methoxyflurane	Small Molecule	76-38-0	Approved\|Investigational	Enzyme
DB01037	Selegiline	Small Molecule	14611-51-9	Approved\|Investigational	Enzyme
DB01043	Memantine	Small Molecule	19982-08-2	Approved\|Investigational	Enzyme
DB01045	Rifampicin	Small Molecule	13292-46-1	Approved	Enzyme
DB01059	Norfloxacin	Small Molecule	70458-96-7	Approved	Enzyme
DB01085	Pilocarpine	Small Molecule	92-13-7	Approved\|Investigational	Enzyme
DB01110	Miconazole	Small Molecule	22916-47-8	Approved\|Investigational	Enzyme
DB01115	Nifedipine	Small Molecule	21829-25-4	Approved	Enzyme
DB01118	Amiodarone	Small Molecule	1951-25-3	Approved\|Investigational	Enzyme
DB01151	Desipramine	Small Molecule	50-47-5	Approved\|Investigational	Enzyme
DB01156	Bupropion	Small Molecule	34911-55-2	Approved	Enzyme
DB01159	Halothane	Small Molecule	151-67-7	Approved	Enzyme
DB01174	Phenobarbital	Small Molecule	50-06-6	Approved\|Investigational	Enzyme
DB01181	Ifosfamide	Small Molecule	3778-73-2	Approved	Enzyme
DB01191	Dexfenfluramine	Small Molecule	3239-44-9	Approved\|Illicit\|Investigational\|Withdrawn	Enzyme
DB01213	Fomepizole	Small Molecule	7554-65-6	Approved	Enzyme
DB01234	Dexamethasone	Small Molecule	50-02-2	Approved\|Investigational	Enzyme
DB01236	Sevoflurane	Small Molecule	28523-86-6	Approved	Enzyme
DB01274	Arformoterol	Small Molecule	67346-49-0	Approved\|Investigational	Enzyme
DB01351	Amobarbital	Small Molecule	57-43-2	Approved\|Illicit	Enzyme
DB01435	Antipyrine	Small Molecule	60-80-0	Approved\|Investigational	Enzyme
DB01544	Flunitrazepam	Small Molecule	1622-62-4	Approved\|Illicit	Enzyme
DB03783	Phenacetin	Small Molecule	62-44-2	Withdrawn	Enzyme
DB04841	Flunarizine	Small Molecule	52468-60-7	Approved	Enzyme
DB04871	Lorcaserin	Small Molecule	616202-92-7	Approved	Enzyme
DB04953	Ezogabine	Small Molecule	150812-12-7	Approved\|Investigational	Enzyme
DB04977	Plitidepsin	Small Molecule	137219-37-5	Investigational	Enzyme
DB06292	Dapagliflozin	Small Molecule	461432-26-8	Approved	Enzyme
DB06470	clomethiazole	Small Molecule		Investigational	Enzyme
DB06712	Nilvadipine	Small Molecule	75530-68-6	Approved\|Investigational	Enzyme
DB06729	Sulfaphenazole	Small Molecule	526-08-9	Approved	Enzyme
DB06739	Seratrodast	Small Molecule	112665-43-7	Approved	Enzyme
DB09068	Vortioxetine	Small Molecule	508233-74-7	Approved\|Investigational	Enzyme
DB09256	Tegafur	Small Molecule	17902-23-7	Approved\|Investigational	Enzyme
DB09327	Tegafur-uracil	Small Molecule	74578-38-4	Approved\|Investigational	Enzyme
DB13179	Troleandomycin	Small Molecule	2751-09-9	Approved	Enzyme

ID	Drug Name	Action	PubMed
C495657	1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane	"CYP2A6 protein results in increased chemical synthesis of 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane"	9733665
C074153	1,4-phenylenebis(methylene)selenocyanate	"1,4-phenylenebis(methylene)selenocyanate binds to and results in decreased activity of CYP2A6 protein"	21732699
C053084	1,7-dimethyluric acid	"CYP2A6 protein results in increased chemical synthesis of 1,7-dimethyluric acid"	12505289
C053084	1,7-dimethyluric acid	"[CYP2A6 protein results in increased metabolism of 1,7-dimethylxanthine] which results in increased chemical synthesis of 1,7-dimethyluric acid"	19215233
C021183	1,7-dimethylxanthine	"CYP2A6 protein affects the metabolism of and results in increased activity of 1,7-dimethylxanthine"	12505289
C021183	1,7-dimethylxanthine	"CYP2A6 protein polymorphism results in increased hydroxylation of 1,7-dimethylxanthine"	15980104
C021183	1,7-dimethylxanthine	"CYP2A6 protein results in increased hydroxylation of 1,7-dimethylxanthine"	15980104
C021183	1,7-dimethylxanthine	"CYP2A6 protein results in increased metabolism of 1,7-dimethylxanthine"	17916905\|1921523
C021183	1,7-dimethylxanthine	"[CYP2A6 protein results in increased metabolism of 1,7-dimethylxanthine] which results in increased chemical synthesis of 1,7-dimethyluric acid"	19215233
C478004	1-hydroxy-2,3,5-trimethoxyxanthone	"CYP2A6 protein results in increased metabolism of 1-hydroxy-2,3,5-trimethoxyxanthone"	24380714
C029350	1-naphthol	CYP2A6 protein results in increased abundance of 1-naphthol	16243959\|2713713
C029350	1-naphthol	[CYP2A6 protein results in increased oxidation of naphthalene] which results in increased abundance of 1-naphthol	27137136
C024336	1-phenylazo-2-naphthol	CYB5A protein promotes the reaction [CYP2A6 protein results in increased oxidation of 1-phenylazo-2-naphthol]	17159775
C024336	1-phenylazo-2-naphthol	CYP2A6 protein results in increased oxidation of 1-phenylazo-2-naphthol	17159775
C511295	2,2',4,4'-tetrabromodiphenyl ether	"2,2',4,4'-tetrabromodiphenyl ether results in increased expression of CYP2A6 protein"	16603574
C009828	2,4,5,2',5'-pentachlorobiphenyl	"CYP2A6 protein results in increased metabolism of 2,4,5,2',5'-pentachlorobiphenyl"	16616008
C028519	2,6-dimethylnaphthalene	"CYP2A6 protein results in increased oxidation of 2,6-dimethylnaphthalene"	17156750
C007766	2,6-xylidine	"CYP2A6 protein results in increased hydroxylation of 2,6-xylidine"	11409937
C003898	2-anisidine	CYP2A6 protein results in increased oxidation of 2-anisidine	15828049
C586542	2'-(glutathion-S-yl)-deschlorodiclofenac	[CYP2A6 protein co-treated with GSTP1 protein co-treated with Glutathione] results in increased abundance of 2'-(glutathion-S-yl)-deschlorodiclofenac	24246759
C045022	2-propyl-4-pentenoic acid	CYP2A6 protein results in increased chemical synthesis of 2-propyl-4-pentenoic acid	16945988
C018855	2-tert-butylhydroquinone	2-tert-butylhydroquinone results in increased expression of CYP2A6 mRNA	24830941
C026114	2-xylene	CYP2A6 protein results in increased oxidation of 2-xylene	17156750
C065776	3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one	"CYP2A6 gene polymorphism affects the metabolism of and affects the susceptibility to 3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one"	10087035
C065776	3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one	"CYP2A6 protein results in increased metabolism of 3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one"	12464242
C031285	3-xylene	CYP2A6 protein results in increased oxidation of 3-xylene	17156750
C031285	3-xylene	3-xylene binds to [3-xylene binds to CYP2A6 protein]	18247580
C031285	3-xylene	3-xylene binds to CYP2A6 protein	18247580
C031285	3-xylene	4-xylene binds to [3-xylene binds to CYP2A6 protein]	18247580
C031285	3-xylene	CYP2A6 protein results in increased oxidation of 3-xylene	18247580
C106616	4,4'-dimethylbiphenyl	"CYP2A6 protein results in increased oxidation of 4,4'-dimethylbiphenyl"	17156750
C543441	4,4'-methanol-bisbenzonitrile	"CYP2A6 gene polymorphism affects the chemical synthesis of 4,4'-methanol-bisbenzonitrile"	19845430
C543441	4,4'-methanol-bisbenzonitrile	"CYP2A6 protein results in increased chemical synthesis of 4,4'-methanol-bisbenzonitrile"	19845430
C545880	4,5-dihydropyrazole-1,5-dicarboxylic acid 1-((4-chlorophenyl)-amide) 5-(2-oxo-2H-(1,3')bipyridinyl-6'-yl)-amide	"CYP2A6 protein results in increased metabolism of 4,5-dihydropyrazole-1,5-dicarboxylic acid 1-((4-chlorophenyl)-amide) 5-(2-oxo-2H-(1,3')bipyridinyl-6'-yl)-amide"	19697924
C091207	4-hydroxyvalproate	CYP2A6 protein results in increased chemical synthesis of 4-hydroxyvalproate	16945988
C099565	4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol	CYP2A6 protein results in increased metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol	17454707
C005306	4-nitroanisole	CYP2A6 protein results in increased metabolism of 4-nitroanisole	12464242
C024836	4-nitrophenol	CYP2A6 protein results in increased hydroxylation of 4-nitrophenol	15135088
C016583	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	CYB5A protein promotes the reaction [CYP2A6 protein results in increased activity of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone]	15728263
C016583	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	CYP2A6 protein affects the metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	12920169
C016583	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	CYP2A6 protein affects the metabolism of and results in increased activity of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	11774366
C016583	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	CYP2A6 protein results in increased activity of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	15728263
C016583	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	CYP2A6 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	12115524\|1221467
C016583	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	CYP2A6 protein results in increased metabolism of and results in increased activity of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	11259349\|1168432
C016583	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	CYP2A6 results in increased activity of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	21473878
C016583	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	CYP2A6 results in increased hydroxylation of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	21473878
C016583	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	CYP2A6 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	17454707\|2522179
C031286	4-xylene	CYP2A6 protein results in increased oxidation of 4-xylene	17156750
C031286	4-xylene	4-xylene binds to [3-xylene binds to CYP2A6 protein]	18247580
C031286	4-xylene	4-xylene binds to CYP2A6 protein	18247580
C031286	4-xylene	CYP2A6 protein results in increased oxidation of 4-xylene	18247580
C529169	5-chlorotryptamine	5-chlorotryptamine analog results in decreased activity of CYP2A6 protein	26599973
C529169	5-chlorotryptamine	[5-chlorotryptamine analog results in decreased activity of CYP2A6 protein] which results in decreased metabolism of coumarin	26599973
C051101	5-fluoro-alpha-methyltryptamine	5-fluoro-alpha-methyltryptamine results in decreased activity of CYP2A6 protein	26599973
C051101	5-fluoro-alpha-methyltryptamine	[5-fluoro-alpha-methyltryptamine results in decreased activity of CYP2A6 protein] which results in decreased metabolism of coumarin	26599973
C091208	5-hydroxyvalproate	CYP2A6 protein results in increased chemical synthesis of 5-hydroxyvalproate	16945988
C027552	5-methyltryptamine	5-methyltryptamine analog results in decreased activity of CYP2A6 protein	26599973
C027552	5-methyltryptamine	[5-methyltryptamine analog results in decreased activity of CYP2A6 protein] which results in decreased metabolism of coumarin	26599973
C475093	6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime	"6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2A6 mRNA"	16857725
C073279	6-phenylhexyl isothiocyanate	6-phenylhexyl isothiocyanate results in decreased activity of CYP2A6 protein	10616189
C031477	7-hydroxycoumarin	CYP2A6 protein results in increased chemical synthesis of 7-hydroxycoumarin	10616189\|1137656
C031477	7-hydroxycoumarin	nitrosobenzylmethylamine inhibits the reaction [CYP2A6 protein results in increased chemical synthesis of 7-hydroxycoumarin]	10616189
C036696	7-methyltryptamine	7-methyltryptamine analog results in decreased activity of CYP2A6 protein	26599973
C036696	7-methyltryptamine	[7-methyltryptamine analog results in decreased activity of CYP2A6 protein] which results in decreased metabolism of coumarin	26599973
C042552	acenaphthene	CYP2A6 protein results in increased oxidation of acenaphthene	25642975
C042552	acenaphthene	[CYP2A6 protein results in increased oxidation of acenaphthene] which results in increased chemical synthesis of acenaphthene-1-ol	25642975
C023723	acenaphthene-1-ol	[CYP2A6 protein results in increased oxidation of acenaphthene] which results in increased chemical synthesis of acenaphthene-1-ol	25642975
C042553	acenaphthylene	CYP2A6 protein results in increased oxidation of acenaphthylene	25642975
C042553	acenaphthylene	CYP2A6 protein results in increased oxidation of acenaphthylene metabolite	25642975
D000082	Acetaminophen	Acetaminophen results in decreased expression of CYP2A6 mRNA	29067470
D000082	Acetaminophen	Acetaminophen results in increased expression of CYP2A6 mRNA	26690555
D000082	Acetaminophen	CYP2A6 results in increased metabolism of Acetaminophen	20566340
C016601	afimoxifene	afimoxifene inhibits the reaction [Estradiol results in increased expression of CYP2A6 mRNA]	17646279
C016601	afimoxifene	afimoxifene results in decreased expression of CYP2A6 mRNA	29285606
D016604	Aflatoxin B1	Aflatoxin B1 affects the expression of CYP2A6 protein	20106945
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased expression of CYP2A6 mRNA	27153756
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased methylation of CYP2A6 gene	27153756
D016604	Aflatoxin B1	CYP2A6 protein results in increased susceptibility to Aflatoxin B1	11189750
D016604	Aflatoxin B1	CYP2A6 protein affects the susceptibility to Aflatoxin B1	22743290
D016604	Aflatoxin B1	CYP2A6 protein results in increased metabolism of and results in increased activity of Aflatoxin B1	16470306
C010078	alizarin	alizarin results in decreased activity of CYP2A6 protein	12379470
C038491	allyl sulfide	allyl sulfide inhibits the reaction [Ethanol results in increased expression of CYP2A6 mRNA]	22530035
C038491	allyl sulfide	allyl sulfide inhibits the reaction [Ethanol results in increased expression of CYP2A6 protein]	22530035
C038491	allyl sulfide	allyl sulfide results in decreased activity of CYP2A6 protein	18339364
D017962	alpha-Linolenic Acid	alpha-Linolenic Acid results in increased expression of CYP2A6 mRNA	28555106
D017962	alpha-Linolenic Acid	alpha-Linolenic Acid results in increased expression of CYP2A6 protein	28555106
D017962	alpha-Linolenic Acid	NFE2L2 protein promotes the reaction [alpha-Linolenic Acid results in increased expression of CYP2A6 mRNA]	28555106
D017962	alpha-Linolenic Acid	NFE2L2 protein promotes the reaction [alpha-Linolenic Acid results in increased expression of CYP2A6 protein]	28555106
C008615	alpha-nicotyrine	alpha-nicotyrine inhibits the reaction [CYP2A6 protein results in increased hydroxylation of coumarin]	22486895
C008615	alpha-nicotyrine	alpha-nicotyrine results in decreased activity of CYP2A6 protein	22486895\|2522179
D000638	Amiodarone	CYP2A6 protein results in decreased susceptibility to Amiodarone	26477383
C039726	artesunate	CYP2A6 protein affects the metabolism of artesunate	12920490
D001205	Ascorbic Acid	Ascorbic Acid inhibits the reaction [Ethanol results in increased expression of CYP2A6 mRNA]	22530035
D001205	Ascorbic Acid	Ascorbic Acid inhibits the reaction [Ethanol results in increased expression of CYP2A6 protein]	22530035
D001205	Ascorbic Acid	Ascorbic Acid results in decreased activity of CYP2A6 protein	17512695
D001280	Atrazine	Atrazine results in increased expression of CYP2A6 mRNA	22310298
C061004	benidipine	benidipine results in increased expression of CYP2A6 mRNA	27732883
C061004	benidipine	benidipine results in increased expression of CYP2A6 protein	27732883
C032175	benzaldehyde	CYP2A6 protein results in increased chemical synthesis of benzaldehyde	10616189
D019324	beta-Naphthoflavone	beta-Naphthoflavone results in increased expression of CYP2A6 mRNA	19118567
D019817	Benzoic Acid	CYP2A6 protein results in increased chemical synthesis of Benzoic Acid	10616189
D001564	Benzo(a)pyrene	Benzo(a)pyrene promotes the reaction [TP53 protein results in increased expression of CYP2A6 mRNA]	26343999
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of CYP2A6 mRNA	20106945
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of CYP2A6 mRNA	26343999
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of CYP2A6 protein	26343999
D019905	Benzyl Alcohol	CYP2A6 protein results in increased chemical synthesis of Benzyl Alcohol	10616189
C054108	benzyl selenocyanate	benzyl selenocyanate binds to and results in decreased activity of CYP2A6 protein	21732699
D004958	Estradiol	afimoxifene inhibits the reaction [Estradiol results in increased expression of CYP2A6 mRNA]	17646279
D004958	Estradiol	ESR1 protein promotes the reaction [Estradiol results in increased expression of CYP2A6 mRNA]	17646279
D004958	Estradiol	Estradiol promotes the reaction [ESR1 protein binds to CYP2A6 promoter]	17646279
D004958	Estradiol	Estradiol results in increased expression of CYP2A6 mRNA	17646279\|2283738
D004958	Estradiol	fulvestrant inhibits the reaction [Estradiol results in increased expression of CYP2A6 mRNA]	17646279
D001663	Bilirubin	Bilirubin inhibits the reaction [Cycloheximide results in decreased expression of CYP2A6 protein]	22465937
D001663	Bilirubin	Bilirubin results in decreased activity of CYP2A6 protein	22465937
D001663	Bilirubin	Bilirubin results in increased expression of and results in increased activity of CYP2A6 protein	22465937
D001663	Bilirubin	Bilirubin results in increased stability of CYP2A6 protein	22465937
D001663	Bilirubin	CYP2A6 protein results in increased oxidation of Bilirubin	22465937
D001663	Bilirubin	[CYP2A6 protein results in increased oxidation of Bilirubin] which results in increased chemical synthesis of Biliverdine	22465937
D001664	Biliverdine	[CYP2A6 protein results in increased oxidation of Bilirubin] which results in increased chemical synthesis of Biliverdine	22465937
C006780	bisphenol A	bisphenol A results in increased expression of CYP2A6 mRNA	26196221
C006780	bisphenol A	bisphenol A results in increased expression of CYP2A6 protein	16603574
C025191	bromodichloromethane	CYP2A6 protein results in increased metabolism of bromodichloromethane	12076521
D002083	Butylated Hydroxyanisole	Butylated Hydroxyanisole results in increased expression of CYP2A6 mRNA	22530035
D002083	Butylated Hydroxyanisole	Butylated Hydroxyanisole results in increased expression of CYP2A6 protein	22530035
D002110	Caffeine	CYP2A6 protein affects the metabolism of and results in increased activity of Caffeine metabolite	12505289
D002110	Caffeine	CYP2A6 protein results in increased metabolism of Caffeine	17916905
D002220	Carbamazepine	Carbamazepine results in increased expression of CYP2A6 mRNA	17112801
C006698	carbendazim	carbendazim results in increased expression of CYP2A6 mRNA	22310298
C035038	carbosulfan	carbosulfan results in increased expression of CYP2A6 mRNA	22310298
D002273	Carcinogens	CYP2A6 protein affects the susceptibility to Carcinogens	12505289
C088453	Celsior	[Celsior co-treated with Phenobarbital] results in increased expression of CYP2A6 mRNA	15448115
C088453	Celsior	Celsior results in decreased activity of CYP2A6 protein	15448115
C088453	Celsior	Celsior results in decreased expression of CYP2A6 mRNA	15448115
C057223	chlorfluazuron	chlorfluazuron results in increased expression of CYP2A6 mRNA	22310298
D020111	Chlorodiphenyl (54% Chlorine)	Chlorodiphenyl (54% Chlorine) results in increased expression of CYP2A6 mRNA	17851650
D002746	Chlorpromazine	Chlorpromazine results in decreased activity of CYP2A6 protein	15135088
D002746	Chlorpromazine	CYP2A6 protein results in decreased susceptibility to Chlorpromazine	26477383
D004390	Chlorpyrifos	Chlorpyrifos results in increased expression of CYP2A6 mRNA	22310298
C029010	cinnamic acid	cinnamic acid analog results in decreased activity of CYP2A6 protein	15072549
D002995	Clofibric Acid	Clofibric Acid results in decreased activity of CYP2A6 protein	11038160
D002995	Clofibric Acid	Clofibric Acid results in decreased expression of CYP2A6 mRNA	11038160
C018021	cobaltous chloride	cobaltous chloride results in increased activity of CYP2A6 protein	11038160
C018021	cobaltous chloride	cobaltous chloride results in increased expression of CYP2A6 mRNA	11038160
D003367	Cotinine	CYP2A6 gene mutant form results in decreased abundance of Cotinine	10668854
D003367	Cotinine	CYP2A6 protein affects the chemical synthesis of Cotinine	23371292
D003367	Cotinine	[CYP2A6 protein affects the metabolism of Nicotine] which affects the chemical synthesis of Cotinine	23371292
D003367	Cotinine	CYP2A6 protein results in increased abundance of Cotinine	24305170
D003367	Cotinine	CYP2A6 protein results in increased chemical synthesis of Cotinine	10999944\|1125934
D003367	Cotinine	CYP2A6 protein results in increased metabolism of Cotinine	12024803\|1240664
D003367	Cotinine	[tryptamine results in decreased activity of CYP2A6 protein] which results in decreased abundance of Cotinine	22498344
D003367	Cotinine	CYP2A6 protein results in increased chemical synthesis of Cotinine	11353760\|2393647
D003367	Cotinine	CYP2A6 protein results in increased metabolism of Cotinine	23936477
D003367	Cotinine	[CYP2A6 protein results in increased metabolism of Cotinine] which results in increased chemical synthesis of hydroxycotinine	23936477
D003367	Cotinine	[CYP2A6 protein results in increased metabolism of Nicotine] which results in increased chemical synthesis of Cotinine	23936477
C030123	coumarin	[5-chlorotryptamine analog results in decreased activity of CYP2A6 protein] which results in decreased metabolism of coumarin	26599973
C030123	coumarin	[5-fluoro-alpha-methyltryptamine results in decreased activity of CYP2A6 protein] which results in decreased metabolism of coumarin	26599973
C030123	coumarin	[5-methyltryptamine analog results in decreased activity of CYP2A6 protein] which results in decreased metabolism of coumarin	26599973
C030123	coumarin	[7-methyltryptamine analog results in decreased activity of CYP2A6 protein] which results in decreased metabolism of coumarin	26599973
C030123	coumarin	coumarin binds to CYP2A6 protein	24924949
C030123	coumarin	coumarin inhibits the reaction [CYP2A6 protein results in increased glutathionylation of lamotrigine]	19961160
C030123	coumarin	coumarin results in decreased activity of CYP2A6 protein	16035375
C030123	coumarin	CYP2A6 exon SNP results in decreased metabolism of coumarin	15618666
C030123	coumarin	CYP2A6 exon SNP results in increased metabolism of coumarin	11237731
C030123	coumarin	CYP2A6 promoter SNP affects the metabolism of coumarin	14583682
C030123	coumarin	CYP2A6 protein affects the metabolism of coumarin	12818727\|1562658
C030123	coumarin	CYP2A6 protein binds to and results in increased metabolism of coumarin	16207711
C030123	coumarin	CYP2A6 protein mutant form affects the metabolism of coumarin	15980104
C030123	coumarin	CYP2A6 protein polymorphism results in increased hydroxylation of coumarin	15681899
C030123	coumarin	CYP2A6 protein results in increased hydroxylation of coumarin	10616189\|1137656
C030123	coumarin	CYP2A6 protein results in increased metabolism of and affects the abundance of coumarin	16126166
C030123	coumarin	CYP2A6 protein results in increased metabolism of coumarin	11504148\|1168432
C030123	coumarin	[indopan analog results in decreased activity of CYP2A6 protein] which results in decreased metabolism of coumarin	26599973
C030123	coumarin	[indopan results in decreased activity of CYP2A6 protein] which results in decreased metabolism of coumarin	26599973
C030123	coumarin	nitrosobenzylmethylamine inhibits the reaction [CYP2A6 protein results in increased hydroxylation of coumarin]	10616189
C030123	coumarin	"[N,N-diisopropyltryptamine analog results in decreased activity of CYP2A6 protein] which results in decreased metabolism of coumarin"	26599973
C030123	coumarin	perfluorooctane sulfonic acid inhibits the reaction [CYP2A6 protein results in increased hydroxylation of coumarin]	21964418
C030123	coumarin	Proadifen inhibits the reaction [CYP2A6 protein results in increased metabolism of coumarin]	8819299
C030123	coumarin	[Tranylcypromine results in decreased activity of CYP2A6 protein] which results in decreased metabolism of coumarin	26599973
C030123	coumarin	[Tryptamines analog results in decreased activity of CYP2A6 protein] which results in decreased metabolism of coumarin	26599973
C030123	coumarin	CYP2A6 protein results in increased hydroxylation of coumarin	12919726
C030123	coumarin	alpha-nicotyrine inhibits the reaction [CYP2A6 protein results in increased hydroxylation of coumarin]	22486895
C030123	coumarin	coumarin results in decreased activity of CYP2A6 protein	16945988\|1996116
C030123	coumarin	CYP2A6 protein results in increased hydroxylation of coumarin	22486895
C030123	coumarin	menthofuran inhibits the reaction [CYP2A6 protein results in increased hydroxylation of coumarin]	22486895
C030123	coumarin	Menthol inhibits the reaction [CYP2A6 protein results in increased hydroxylation of coumarin]	22486895
D003513	Cycloheximide	Bilirubin inhibits the reaction [Cycloheximide results in decreased expression of CYP2A6 protein]	22465937
D003513	Cycloheximide	Cycloheximide results in decreased expression of CYP2A6 protein	22465937
D016572	Cyclosporine	Cyclosporine results in decreased expression of CYP2A6 mRNA	20106945
C037304	cyhalothrin	cyhalothrin results in increased expression of CYP2A6 mRNA	22310298
C089595	cylindrospermopsin	cylindrospermopsin results in decreased expression of CYP2A6 mRNA	23726867
C017160	cypermethrin	cypermethrin results in increased expression of CYP2A6 mRNA	22310298
C017180	decamethrin	decamethrin results in increased expression of CYP2A6 mRNA	22310298
D003671	DEET	CYP2A6 protein results in increased metabolism of DEET	11854147
D003671	DEET	DEET results in increased expression of CYP2A6 mRNA	19326769\|2709163
D003671	DEET	[fipronil co-treated with DEET] results in increased expression of CYP2A6 mRNA	27091632
D003891	Desipramine	Desipramine results in decreased activity of CYP2A6 protein	15135088
D003907	Dexamethasone	Dexamethasone promotes the reaction [HNF4A protein binds to CYP2A6 promoter]	17978169
D003907	Dexamethasone	Dexamethasone results in increased activity of CYP2A6 protein	10923861
D003907	Dexamethasone	Dexamethasone results in increased expression of CYP2A6 mRNA	17978169
D003907	Dexamethasone	Dexamethasone results in increased expression of CYP2A6 protein	17978169
D003907	Dexamethasone	Mifepristone inhibits the reaction [Dexamethasone results in increased expression of CYP2A6 mRNA]	17978169
D003907	Dexamethasone	Mifepristone inhibits the reaction [Dexamethasone results in increased expression of CYP2A6 protein]	17978169
D003907	Dexamethasone	NR3C1 protein affects the reaction [Dexamethasone results in increased expression of CYP2A6 mRNA]	17978169
C028009	diallyl disulfide	diallyl disulfide results in decreased activity of CYP2A6 protein	18339364
C055869	dichlobanil	CYP2A6 protein results in increased metabolism of dichlobanil	12464242
D002945	Cisplatin	CYP2A6 gene polymorphism results in decreased susceptibility to [Cisplatin co-treated with S 1 (combination)]	21364592
C036042	dicyclohexyl phthalate	dicyclohexyl phthalate affects the expression of CYP2A6 mRNA	26924002
D004052	Diethylnitrosamine	CYB5A protein promotes the reaction [CYP2A6 protein results in increased activity of Diethylnitrosamine]	15728263
D004052	Diethylnitrosamine	CYP2A6 protein affects the metabolism of and results in increased activity of Diethylnitrosamine	11600130\|1177436
D004052	Diethylnitrosamine	CYP2A6 protein results in increased activity of Diethylnitrosamine	15728263
D004052	Diethylnitrosamine	CYP2A6 protein results in increased metabolism of Diethylnitrosamine	12214673
D002117	Calcitriol	Calcitriol results in increased expression of CYP2A6 mRNA	21592394
D002117	Calcitriol	[Testosterone co-treated with Calcitriol] results in increased expression of CYP2A6 mRNA	21592394
D004128	Dimethylnitrosamine	CYP2A6 protein results in increased metabolism of and results in increased activity of Dimethylnitrosamine	11960914
D004128	Dimethylnitrosamine	CYP2A6 protein results in increased hydroxylation of Dimethylnitrosamine	12919726
C024629	dimethyl phthalate	dimethyl phthalate affects the expression of CYP2A6 mRNA	26924002
D004121	Dimethyl Sulfoxide	Dimethyl Sulfoxide affects the expression of CYP2A6 mRNA	12843640
C087894	dipropyl sulfide	dipropyl sulfide results in decreased activity of CYP2A6 protein	18339364
D004050	Ditiocarb	Ditiocarb results in decreased activity of CYP2A6 protein	8819299
D004050	Ditiocarb	Ditiocarb results in decreased activity of CYP2A6 protein	10828259\|9103523
D004237	Diuron	Diuron results in increased expression of CYP2A6 mRNA	22310298
D004726	Endosulfan	[Endosulfan co-treated with Tetrachlorodibenzodioxin] results in decreased expression of CYP2A6 mRNA	26159488
C091891	epsilon-viniferin	epsilon-viniferin results in decreased activity of CYP2A6 protein	12818727
C007633	estragole	CYP2A6 protein results in increased hydroxylation of estragole	19920071
D000431	Ethanol	[Nicotine co-treated with Ethanol] results in decreased expression of and results in decreased activity of CYP2A6 protein	22935730
D000431	Ethanol	[Nicotine co-treated with Ethanol] results in decreased expression of CYP2A6 mRNA	22935730
D000431	Ethanol	allyl sulfide inhibits the reaction [Ethanol results in increased expression of CYP2A6 mRNA]	22530035
D000431	Ethanol	allyl sulfide inhibits the reaction [Ethanol results in increased expression of CYP2A6 protein]	22530035
D000431	Ethanol	Ascorbic Acid inhibits the reaction [Ethanol results in increased expression of CYP2A6 mRNA]	22530035
D000431	Ethanol	Ascorbic Acid inhibits the reaction [Ethanol results in increased expression of CYP2A6 protein]	22530035
D000431	Ethanol	[CYP2E1 protein results in increased metabolism of Ethanol] promotes the reaction [Ethanol results in increased expression of CYP2A6]	22530035
D000431	Ethanol	[[Ethanol affects the activity of CYP2E1 protein] which affects the localization of NFE2L2 protein] which results in increased expression of CYP2A6	22530035
D000431	Ethanol	[Ethanol affects the localization of NFE2L2 protein] which results in increased expression of CYP2A6	22530035
D000431	Ethanol	Ethanol results in increased expression of CYP2A6 mRNA	22530035
D000431	Ethanol	Ethanol results in increased expression of CYP2A6 protein	22530035
D000431	Ethanol	Staurosporine inhibits the reaction [Ethanol results in increased expression of CYP2A6 mRNA]	22530035
D000431	Ethanol	Staurosporine inhibits the reaction [Ethanol results in increased expression of CYP2A6 protein]	22530035
D000431	Ethanol	U 0126 inhibits the reaction [Ethanol results in increased expression of CYP2A6 mRNA]	22530035
D000431	Ethanol	U 0126 inhibits the reaction [Ethanol results in increased expression of CYP2A6 protein]	22530035
C098546	ethyl tert-butyl ether	CYP2A6 protein results in increased metabolism of ethyl tert-butyl ether	11504148
D017316	Fadrozole	CYP2A6 protein affects the metabolism of Fadrozole	15980104
D017316	Fadrozole	CYP2A6 protein results in increased metabolism of Fadrozole	12464242\|1248715
D015736	Felodipine	Felodipine results in increased expression of CYP2A6 mRNA	27732883
D015736	Felodipine	Felodipine results in increased expression of CYP2A6 protein	27732883
D005278	Fenitrothion	Fenitrothion results in increased expression of CYP2A6 mRNA	22310298
C017690	fenvalerate	fenvalerate results in increased expression of CYP2A6 mRNA	22310298
C082360	fipronil	[fipronil co-treated with DEET] results in increased expression of CYP2A6 mRNA	27091632
C082360	fipronil	fipronil results in increased expression of CYP2A6 mRNA	27091632
D005472	Fluorouracil	CYP2A6 protein results in increased chemical synthesis of Fluorouracil	11376561\|1821280
D005476	Fluphenazine	Fluphenazine results in decreased activity of CYP2A6 protein	15135088
C070081	fulvestrant	fulvestrant inhibits the reaction [Estradiol results in increased expression of CYP2A6 mRNA]	17646279
D005978	Glutathione	[CYP2A6 protein co-treated with GSTP1 protein co-treated with Glutathione] results in increased abundance of 2'-(glutathion-S-yl)-deschlorodiclofenac	24246759
D006221	Halothane	CYP2A6 protein affects the metabolism of Halothane	9103523
D006221	Halothane	CYP2A6 protein results in increased metabolism of Halothane	12487152\|8886607
D006492	Hempa	CYP2A6 protein results in increased metabolism of Hempa	9007030
C058039	hexafluoron	hexafluoron results in increased expression of CYP2A6 mRNA	22310298
D017313	Fenretinide	Fenretinide results in increased expression of CYP2A6 mRNA	28973697
C001381	hydroxycotinine	CYP2A6 gene polymorphism affects the metabolism of hydroxycotinine	22569203
C001381	hydroxycotinine	CYP2A6 protein results in increased chemical synthesis of hydroxycotinine	12024803\|1614160
C001381	hydroxycotinine	CYP2A6 protein results in increased chemical synthesis of hydroxycotinine	23936477
C001381	hydroxycotinine	[CYP2A6 protein results in increased metabolism of Cotinine] which results in increased chemical synthesis of hydroxycotinine	23936477
D007069	Ifosfamide	CYP2A6 protein affects the hydroxylation of Ifosfamide	12136253
D007203	Indigo Carmine	Indigo Carmine results in decreased activity of CYP2A6 protein	16009655
C030374	indole	CYP2A6 protein results in increased metabolism of indole	16215230
C015293	indopan	indopan analog results in decreased activity of CYP2A6 protein	26599973
C015293	indopan	[indopan analog results in decreased activity of CYP2A6 protein] which results in decreased metabolism of coumarin	26599973
C015293	indopan	indopan results in decreased activity of CYP2A6 protein	26599973
C015293	indopan	[indopan results in decreased activity of CYP2A6 protein] which results in decreased metabolism of coumarin	26599973
C051890	irinotecan	irinotecan metabolite results in decreased activity of CYP2A6 protein	11901092
D007501	Iron	Iron results in increased expression of CYP2A6 protein	11927840
D007510	Isatin	Isatin results in increased expression of CYP2A6 mRNA	15056799
C028904	isoproturon	isoproturon results in increased expression of CYP2A6 mRNA	22310298
D017275	Isradipine	Isradipine results in increased expression of CYP2A6 mRNA	27732883
D017275	Isradipine	Isradipine results in increased expression of CYP2A6 protein	27732883
C047781	lamotrigine	coumarin inhibits the reaction [CYP2A6 protein results in increased glutathionylation of lamotrigine]	19961160
C047781	lamotrigine	CYP2A6 protein results in increased activity of lamotrigine	19961160
C047781	lamotrigine	CYP2A6 protein results in increased glutathionylation of lamotrigine	19961160
C047781	lamotrigine	Tranylcypromine inhibits the reaction [CYP2A6 protein results in increased glutathionylation of lamotrigine]	19961160
C067431	letrozole	CYP2A6 gene polymorphism affects the oxidation of letrozole	19845430
C067431	letrozole	CYP2A6 protein results in increased oxidation of letrozole	19845430
C065427	losigame	CYP2A6 protein results in increased metabolism of losigame	12464242
D008294	Malathion	Malathion results in increased expression of CYP2A6 mRNA	22310298
C501277	Mangifera indica extract	Mangifera indica extract results in decreased activity of CYP2A6 protein	22815239
C013592	mangiferin	mangiferin results in decreased activity of CYP2A6 protein	22815239
C054487	menthofuran	menthofuran inhibits the reaction [CYP2A6 protein results in increased hydroxylation of coumarin]	22486895
C054487	menthofuran	menthofuran results in decreased activity of CYP2A6 protein	10828259\|2248689
D008610	Menthol	Menthol inhibits the reaction [CYP2A6 protein results in increased hydroxylation of coumarin]	22486895
D008610	Menthol	Menthol results in decreased activity of CYP2A6 protein	22486895
D008731	Methoxychlor	CYP2A6 protein results in decreased methylation of Methoxychlor	12167570\|1243379
D008733	Methoxyflurane	CYP2A6 protein results in increased metabolism of Methoxyflurane	12464242\|7879937
D008730	Methoxsalen	Methoxsalen results in decreased activity of CYP2A6 protein	10911933\|1135376
D008730	Methoxsalen	Methoxsalen results in decreased activity of CYP2A6 protein	10828259\|1150612
D008753	Methylenebis(chloroaniline)	CYP2A6 protein results in increased oxidation of Methylenebis(chloroaniline)	1740010
D012862	Skatole	Skatole results in decreased expression of CYP2A6 mRNA	28571685
D012862	Skatole	CYP2A6 gene polymorphism results in increased abundance of Skatole	15265071
D012862	Skatole	CYP2A6 protein results in increased metabolism of Skatole	10828259\|1526507
C043243	methyl tert-butyl ether	CYP2A6 protein results in increased metabolism of methyl tert-butyl ether	11504148
C043243	methyl tert-butyl ether	CYP2A6 protein results in increased hydroxylation of methyl tert-butyl ether	12919726
D015735	Mifepristone	Mifepristone inhibits the reaction [Dexamethasone results in increased expression of CYP2A6 mRNA]	17978169
D015735	Mifepristone	Mifepristone inhibits the reaction [Dexamethasone results in increased expression of CYP2A6 protein]	17978169
C517284	monomethyl phthalate	monomethyl phthalate affects the expression of CYP2A6 mRNA	26924002
C031721	naphthalene	CYP2A6 protein results in increased oxidation of naphthalene	27137136
C031721	naphthalene	[CYP2A6 protein results in increased oxidation of naphthalene] which results in increased abundance of 1-naphthol	27137136
C454678	N-ethyl-3-toluamide	CYP2A6 protein results in increased chemical synthesis of N-ethyl-3-toluamide	11854147
D009529	Nicardipine	Nicardipine results in decreased activity of CYP2A6 protein	15863898
D009538	Nicotine	CYP2A6 protein results in increased metabolism of Nicotine	12488541
D009538	Nicotine	Nicotine results in decreased expression of and results in decreased activity of CYP2A6 protein	12488541
D009538	Nicotine	Nicotine results in decreased expression of CYP2A6 mRNA	12488541
D009538	Nicotine	[Nicotine co-treated with Ethanol] results in decreased expression of and results in decreased activity of CYP2A6 protein	22935730
D009538	Nicotine	[Nicotine co-treated with Ethanol] results in decreased expression of CYP2A6 mRNA	22935730
D009538	Nicotine	Nicotine results in decreased expression of and results in decreased activity of CYP2A6 protein	22935730
D009538	Nicotine	Nicotine results in decreased expression of CYP2A6 mRNA	22935730
D009538	Nicotine	CYP2A6 exon SNP results in decreased oxidation of Nicotine	11237731
D009538	Nicotine	CYP2A6 gene mutant form results in decreased metabolism of Nicotine	10448083\|1066885
D009538	Nicotine	CYP2A6 gene mutant form results in decreased oxidation of Nicotine	20012030
D009538	Nicotine	CYP2A6 gene polymorphism affects the metabolism of and affects the abundance of Nicotine	16141602
D009538	Nicotine	CYP2A6 gene polymorphism affects the metabolism of Nicotine	11180041\|1143450
D009538	Nicotine	CYP2A6 gene polymorphism affects the oxidation of Nicotine	10663384\|1590001
D009538	Nicotine	CYP2A6 gene polymorphism results in increased metabolism of Nicotine	17522595
D009538	Nicotine	CYP2A6 gene SNP results in decreased metabolism of Nicotine	12445030
D009538	Nicotine	CYP2A6 protein affects the metabolism of Nicotine	15980104\|2337129
D009538	Nicotine	[CYP2A6 protein affects the metabolism of Nicotine] which affects the chemical synthesis of Cotinine	23371292
D009538	Nicotine	CYP2A6 protein mutant form affects the metabolism of Nicotine	15980104
D009538	Nicotine	CYP2A6 protein results in increased metabolism of and results in decreased activity of Nicotine	10999944\|1125934
D009538	Nicotine	CYP2A6 protein results in increased metabolism of Nicotine	10911933\|1135376
D009538	Nicotine	CYP2A6 protein results in increased oxidation of Nicotine	11684323\|1250434
D009538	Nicotine	CYP2B6 gene polymorphism affects the reaction [CYP2A6 protein results in increased metabolism of Nicotine]	18004205
D009538	Nicotine	Nicotine results in increased expression of CYP2A6 mRNA	22498344
D009538	Nicotine	Nicotine results in increased expression of CYP2A6 protein	22498344
D009538	Nicotine	Tranylcypromine inhibits the reaction [CYP2A6 protein results in increased metabolism of Nicotine]	11353760
D009538	Nicotine	[tryptamine results in decreased activity of CYP2A6 protein] which results in decreased abundance of Nicotine metabolite	22498344
D009538	Nicotine	CYP2A6 protein results in increased hydroxylation of Nicotine	12919726
D009538	Nicotine	CYP2A6 protein results in increased metabolism of Nicotine	15735610\|1685772
D009538	Nicotine	[CYP2A6 protein results in increased metabolism of Nicotine] which results in increased chemical synthesis of Cotinine	23936477
D009538	Nicotine	CYP2A6 protein results in increased oxidation of Nicotine	16470306
C034629	nicotine imine	nicotine imine results in decreased activity of CYP2A6 protein	25221795
D009602	Nitrosamines	CYP2A6 gene polymorphism affects the metabolism of Nitrosamines	22569203
D009602	Nitrosamines	CYP2A6 protein affects the metabolism of and results in increased activity of Nitrosamines	12505289
D009602	Nitrosamines	CYP2A6 protein results in increased metabolism of and results in increased activity of Nitrosamines	12487152
D009602	Nitrosamines	CYP2A6 protein results in increased metabolism of and results in increased activity of Nitrosamines	16470306
C014707	nitrosobenzylmethylamine	CYP2A6 protein results in increased metabolism of nitrosobenzylmethylamine	10616189
C014707	nitrosobenzylmethylamine	nitrosobenzylmethylamine inhibits the reaction [CYP2A6 protein results in increased chemical synthesis of 7-hydroxycoumarin]	10616189
C014707	nitrosobenzylmethylamine	nitrosobenzylmethylamine inhibits the reaction [CYP2A6 protein results in increased hydroxylation of coumarin]	10616189
C014707	nitrosobenzylmethylamine	CYP2A6 protein results in increased hydroxylation of nitrosobenzylmethylamine	12919726
D009242	N-Nitrosopyrrolidine	CYP2A6 protein affects the metabolism of and results in increased activity of N-Nitrosopyrrolidine	11774366
D009242	N-Nitrosopyrrolidine	CYP2A6 protein results in increased metabolism of N-Nitrosopyrrolidine	12214673
C062567	N-methyl-N-2-(methylsulfinyl)ethylpropionic acid amide	CYP2A6 protein results in increased activity of N-methyl-N-2-(methylsulfinyl)ethylpropionic acid amide	15725615
C574385	N,N-didesmethyl-4-hydroxytamoxifen	"CYP2A6 protein results in increased metabolism of N,N-didesmethyl-4-hydroxytamoxifen"	29285606
C574385	N,N-didesmethyl-4-hydroxytamoxifen	"[CYP2A6 protein results in increased metabolism of N,N-didesmethyl-4-hydroxytamoxifen] which results in increased abundance of N,N-didesmethyl-4-hydroxytamoxifen"	29285606
C033695	N,N-diisopropyltryptamine	"N,N-diisopropyltryptamine analog results in decreased activity of CYP2A6 protein"	26599973
C033695	N,N-diisopropyltryptamine	"[N,N-diisopropyltryptamine analog results in decreased activity of CYP2A6 protein] which results in decreased metabolism of coumarin"	26599973
C010257	N'-nitrosoanabasine	CYP2A6 protein affects the metabolism of and results in increased activity of N'-nitrosoanabasine	11774366
C010257	N'-nitrosoanabasine	CYP2A6 protein results in increased metabolism of N'-nitrosoanabasine	12214673
C032978	N'-nitrosoanatabine	CYP2A6 protein affects the metabolism of and results in increased activity of N'-nitrosoanatabine	11774366
C032978	N'-nitrosoanatabine	CYP2A6 protein results in increased metabolism of N'-nitrosoanatabine	12214673
C013161	N-nitroso(di-n-propyl)amine	CYB5A protein promotes the reaction [CYP2A6 protein results in increased activity of N-nitroso(di-n-propyl)amine]	15728263
C013161	N-nitroso(di-n-propyl)amine	CYP2A6 protein affects the metabolism of and results in increased activity of N-nitroso(di-n-propyl)amine	11600130
C013161	N-nitroso(di-n-propyl)amine	CYP2A6 protein affects the metabolism of N-nitroso(di-n-propyl)amine	10910959
C013161	N-nitroso(di-n-propyl)amine	CYP2A6 protein results in increased activity of N-nitroso(di-n-propyl)amine	15728263
C036676	N-nitrosoguvacoline	CYP2A6 protein results in increased activity of N-nitrosoguvacoline	15725615
C002741	N-nitrosomorpholine	CYP2A6 protein affects the metabolism of and results in increased activity of N-nitrosomorpholine	11774366
C008655	N'-nitrosonornicotine	CYP2A6 protein affects the metabolism of and results in increased activity of N'-nitrosonornicotine	11774366
C008655	N'-nitrosonornicotine	CYP2A6 protein results in increased hydroxylation of N'-nitrosonornicotine	9029045
C008655	N'-nitrosonornicotine	CYP2A6 protein results in increased metabolism of N'-nitrosonornicotine	12214673\|1901872
C002743	N-nitrosopiperidine	CYP2A6 protein affects the metabolism of and results in increased activity of N-nitrosopiperidine	11774366
C002743	N-nitrosopiperidine	CYP2A6 protein results in increased metabolism of N-nitrosopiperidine	12214673
C041288	n-propyl disulfide	n-propyl disulfide results in decreased activity of CYP2A6 protein	18339364
C464660	obeticholic acid	obeticholic acid results in increased expression of CYP2A6 mRNA	27939613
C025589	ochratoxin A	ochratoxin A results in decreased expression of CYP2A6 mRNA	26505656
C025589	ochratoxin A	ochratoxin A results in decreased expression of CYP2A6 mRNA	14994279
D019787	Linoleic Acid	Linoleic Acid results in increased expression of CYP2A6 mRNA	28555106
D019787	Linoleic Acid	Linoleic Acid results in increased expression of CYP2A6 protein	28555106
D019787	Linoleic Acid	NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of CYP2A6 mRNA]	28555106
D019787	Linoleic Acid	NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of CYP2A6 protein]	28555106
D019301	Oleic Acid	Oleic Acid results in increased expression of CYP2A6 mRNA	28555106
D019301	Oleic Acid	Oleic Acid results in increased expression of CYP2A6 protein	28555106
D016566	Organoselenium Compounds	Organoselenium Compounds binds to and results in decreased activity of CYP2A6 protein	21732699
D010278	Parathion	Parathion results in increased expression of CYP2A6 mRNA	26196221
D010278	Parathion	Parathion results in increased expression of CYP2A6 protein	26196221
C076994	perfluorooctane sulfonic acid	perfluorooctane sulfonic acid inhibits the reaction [CYP2A6 protein results in increased hydroxylation of coumarin]	21964418
D026023	Permethrin	Permethrin results in increased expression of CYP2A6 mRNA	19326768
C058305	phenethyl isothiocyanate	phenethyl isothiocyanate results in decreased activity of CYP2A6 protein	10616189
D010634	Phenobarbital	[Celsior co-treated with Phenobarbital] results in increased expression of CYP2A6 mRNA	15448115
D010634	Phenobarbital	Phenobarbital results in increased activity of CYP2A6 protein	11038160\|2231029
D010634	Phenobarbital	Phenobarbital results in increased expression of CYP2A6 mRNA	11038160\|1562911
C008838	phenthoate	phenthoate results in increased expression of CYP2A6 mRNA	22310298
D010862	Pilocarpine	Pilocarpine results in decreased activity of CYP2A6 protein	12464242
D011335	Proadifen	Proadifen inhibits the reaction [CYP2A6 protein results in increased metabolism of coumarin]	8819299
C024273	profenofos	profenofos results in increased expression of CYP2A6 mRNA	22310298
D011374	Progesterone	Progesterone results in increased expression of CYP2A6 mRNA	22837389
C531209	propargyl ether	propargyl ether analog binds to CYP2A6 protein	27137136
C511975	purpurin	purpurin results in decreased activity of CYP2A6 protein	12379470
C031280	pyrazole	pyrazole results in increased activity of CYP2A6 protein	11038160
C031280	pyrazole	pyrazole results in increased expression of CYP2A6 mRNA	11038160
D011794	Quercetin	Quercetin results in increased activity of CYP2A6 protein	19215233
C037219	quinoline	CYP2A6 protein results in increased metabolism of quinoline	8824525
D012293	Rifampin	Rifampin promotes the reaction [NR1I2 protein binds to CYP2A6 promoter]	16857725
D012293	Rifampin	Rifampin promotes the reaction [PPARGC1A protein binds to CYP2A6 promoter]	16857725
D012293	Rifampin	Rifampin results in increased expression of CYP2A6 mRNA	15629111\|1685772
D012293	Rifampin	Rifampin results in increased expression of CYP2A6 protein	14709624\|2403885
D012293	Rifampin	[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP2A6 mRNA	29162470
C089730	rosiglitazone	rosiglitazone results in decreased expression of CYP2A6 mRNA	25572481
C079198	S 1 (combination)	CYP2A6 gene polymorphism affects the metabolism of S 1 (combination)	18212800
C079198	S 1 (combination)	CYP2A6 gene polymorphism results in decreased susceptibility to [Cisplatin co-treated with S 1 (combination)]	21364592
D012451	Safrole	Safrole results in decreased activity of CYP2A6 protein	15778010
C009250	sevoflurane	CYP2A6 protein results in increased metabolism of sevoflurane	7879937
D020123	Sirolimus	Sirolimus results in decreased expression of CYP2A6 protein	25929522
D019311	Staurosporine	Staurosporine inhibits the reaction [Ethanol results in increased expression of CYP2A6 mRNA]	22530035
D019311	Staurosporine	Staurosporine inhibits the reaction [Ethanol results in increased expression of CYP2A6 protein]	22530035
C031183	stearic acid	stearic acid results in increased expression of CYP2A6 mRNA	28555106
C031183	stearic acid	stearic acid results in increased expression of CYP2A6 protein	28555106
C016766	sulforafan	[sulforafan results in increased activity of NFE2L2 protein] which results in increased expression of CYP2A6 mRNA	20887713
D013629	Tamoxifen	Tamoxifen results in increased expression of CYP2A6 protein	19812351
C082026	tebufenozide	tebufenozide results in increased expression of CYP2A6 mRNA	22310298
D005641	Tegafur	CYP2A6 gene polymorphism affects the metabolism of Tegafur	18212800
D005641	Tegafur	CYP2A6 protein affects the metabolism of and results in increased activity of Tegafur	15980104
D005641	Tegafur	CYP2A6 protein mutant form affects the metabolism of Tegafur	15980104
D005641	Tegafur	CYP2A6 protein mutant form results in decreased activity of Tegafur	15980104
D005641	Tegafur	CYP2A6 protein results in increased metabolism of Tegafur	11376561\|1217222
D005641	Tegafur	CYP2A6 protein results in increased susceptibility to Tegafur	11376561
C096680	tertiary-amyl methyl ether	CYP2A6 protein results in increased metabolism of tertiary-amyl methyl ether	11504148
D013739	Testosterone	[Testosterone co-treated with Calcitriol] results in increased expression of CYP2A6 mRNA	21592394
D013739	Testosterone	Testosterone results in increased expression of CYP2A6 mRNA	21592394
D013749	Tetrachlorodibenzodioxin	[Endosulfan co-treated with Tetrachlorodibenzodioxin] results in decreased expression of CYP2A6 mRNA	26159488
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP2A6 mRNA	29162470
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of CYP2A6 mRNA	28571685
D013881	Thioridazine	Thioridazine results in decreased activity of CYP2A6 protein	15135088
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution affects the activity of CYP2A6 protein	22486895
C507866	trans-1,2-dihydro-1,2-naphthalenediol	"CYP2A6 protein results in increased abundance of trans-1,2-dihydro-1,2-naphthalenediol"	16243959
D014191	Tranylcypromine	Tranylcypromine inhibits the reaction [CYP2A6 protein results in increased glutathionylation of lamotrigine]	19961160
D014191	Tranylcypromine	Tranylcypromine inhibits the reaction [CYP2A6 protein results in increased metabolism of Nicotine]	11353760
D014191	Tranylcypromine	Tranylcypromine results in decreased activity of CYP2A6 protein	10911933\|1135376
D014191	Tranylcypromine	[Tranylcypromine results in decreased activity of CYP2A6 protein] which results in decreased metabolism of coumarin	26599973
D014191	Tranylcypromine	Tranylcypromine results in decreased activity of CYP2A6 protein	19961160
D014212	Tretinoin	Tretinoin results in increased expression of CYP2A6 mRNA	21376804
C030820	tryptamine	tryptamine results in decreased activity of CYP2A6 protein	11353760
C030820	tryptamine	[tryptamine results in decreased activity of CYP2A6 protein] which results in decreased abundance of Cotinine	22498344
C030820	tryptamine	[tryptamine results in decreased activity of CYP2A6 protein] which results in decreased abundance of Nicotine metabolite	22498344
C030820	tryptamine	tryptamine results in decreased activity of CYP2A6 protein	22498344
D014363	Tryptamines	Tryptamines analog results in decreased activity of CYP2A6 protein	26599973
D014363	Tryptamines	[Tryptamines analog results in decreased activity of CYP2A6 protein] which results in decreased metabolism of coumarin	26599973
C113580	U 0126	U 0126 inhibits the reaction [Ethanol results in increased expression of CYP2A6 mRNA]	22530035
C113580	U 0126	U 0126 inhibits the reaction [Ethanol results in increased expression of CYP2A6 protein]	22530035
D014635	Valproic Acid	CYP2A6 protein results in increased metabolism of Valproic Acid	12487152\|1694598
C052875	verbenone	CYP2A6 protein results in increased metabolism of verbenone	12867494

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005506	iron ion binding	-	IEA	-
GO:0008389	coumarin 7-hydroxylase activity	-	IDA	16086027 19029318 19651758
GO:0008389	coumarin 7-hydroxylase activity	-	TAS	-
GO:0008392	arachidonic acid epoxygenase activity	-	IBA	21873635
GO:0008395	steroid hydroxylase activity	-	IBA	21873635
GO:0016712	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	-	IBA	21873635
GO:0016712	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	-	IEA	-
GO:0019899	enzyme binding	-	IPI	15680923
GO:0020037	heme binding	-	IBA	21873635
GO:0020037	heme binding	-	IDA	16086027

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0006082	organic acid metabolic process	-	IBA	21873635
GO:0006805	xenobiotic metabolic process	-	IBA	21873635
GO:0008202	steroid metabolic process	-	IMP	18356043
GO:0009804	coumarin metabolic process	-	IBA	21873635
GO:0009804	coumarin metabolic process	-	IDA	19651758
GO:0009804	coumarin metabolic process	-	TAS	-
GO:0017144	drug metabolic process	-	IDA	19651758
GO:0017144	drug metabolic process	-	IMP	18356043
GO:0042738	exogenous drug catabolic process	-	IBA	21873635
GO:0042738	exogenous drug catabolic process	-	IDA	15680923
GO:0046226	coumarin catabolic process	-	IDA	19029318
GO:0055114	oxidation-reduction process	-	IBA	21873635
GO:0055114	oxidation-reduction process	-	IEA	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005737	cytoplasm	-	IBA	21873635
GO:0005789	endoplasmic reticulum membrane	-	TAS	-
GO:0005881	cytoplasmic microtubule	-	IDA	23264731
GO:0031090	organelle membrane	-	IEA	-
GO:0043231	intracellular membrane-bounded organelle	-	IBA	21873635

KEGG ID	KEGG Term
hsa00232	Caffeine metabolism
hsa00830	Retinol metabolism
hsa00982	Drug metabolism - cytochrome P450
hsa00983	Drug metabolism - other enzymes
hsa01100	Metabolic pathways

Reactome ID	Reactome Term	Evidence
R-HSA-1430728	Metabolism	TAS
R-HSA-211859	Biological oxidations	TAS
R-HSA-211897	Cytochrome P450 - arranged by substrate type	TAS
R-HSA-211945	Phase I - Functionalization of compounds	TAS
R-HSA-211981	Xenobiotics	TAS
R-HSA-211999	CYP2E1 reactions	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
24045616	Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms. (2014 Jan 15)	Bloom AJ	Hum Mol Genet
22001743	Corneal damage and lacrimal gland dysfunction in a smoking rat model. (2011 Dec 15)	Higuchi A	Free Radic Biol Med
21784037	The influence of CYP2A6 polymorphisms and cadmium on nicotine metabolism in Thai population. (2009 Nov)	Apinan R	Environ Toxicol Pharmacol
16402128	Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. (2006 Apr)	Malaiyandi V	Mol Psychiatry
27815364	Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors. (2017 Jan)	Tanner JA	J Pharmacol Exp Ther
12521401	Factors influencing cotinine half-life during smoking abstinence in African American and Caucasian women. (2002 Nov)	Ahijevych KL	Nicotine Tob Res
28181923	Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer. (2017 May)	Tanner JA	Pharmacogenet Genomics
24859605	Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice. (2014 Oct)	Bagdas D	Neuropharmacology
21778150	A preliminary analysis of interactions between genotype, retrospective ADHD symptoms, and initial reactions to smoking in a sample of young adults. (2012 Feb)	Bidwell LC	Nicotine Tob Res
21432295	Genetic polymorphisms ofCYP2A6 andCYP2E1 with tobacco smoking is not associated with risk of urothelial cancer. (2002 Jul)	Tsukino H	Environ Health Prev Med
28556459	Does coffee consumption impact on heaviness of smoking? (2017 Oct)	Ware JJ	Addiction
16785264	Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment. (2006 Jul)	Lee AM	J Psychopharmacol
23674838	Stability of the nicotine metabolite ratio in smokers of progressively reduced nicotine content cigarettes. (2013 Nov)	St Helen G	Nicotine Tob Res
28290528	Nicotine dependence is associated with functional variation in FMO3, an enzyme that metabolizes nicotine in the brain. (2018 Jan)	Teitelbaum AM	Pharmacogenomics J
26081405	[Association of cytochrome P450 2A6 gene polymorphisms with smoking behaviors:a Meta-analysis]. (2015 Feb)	Pan L	Zhonghua Yu Fang Yi Xue Za Zhi
26132489	Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption. (2015)	Bergen AW	PLoS One
28583088	Uncovering the transcriptomic and epigenomic landscape of nicotinic receptor genes in non-neuronal tissues. (2017 Jun 5)	Zhang B	BMC Genomics
17112802	CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. (2006 Nov)	Benowitz NL	Clin Pharmacol Ther
20717551	Biomonitoring of urinary cotinine concentrations associated with plasma levels of nicotine metabolites after daily cigarette smoking in a male Japanese population. (2010 Jul)	Nagano T	Int J Environ Res Public Health
14633739	Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. (2003 Nov 15)	Wang H	Cancer Res
28856944	Inhibition of human cytochromes P450 2A6 and 2A13 by flavonoids, acetylenic thiophenes and sesquiterpene lactones from Pluchea indica and Vernonia cinerea. (2017 Dec)	Boonruang S	J Enzyme Inhib Med Chem
15940289	Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort. (2005)	Gambier N	Pharmacogenomics J
12708602	Single copy of variant CYP2A6 alleles does not confer susceptibility to liver dysfunction in patients treated with coumarin. (2003 Apr)	Burian M	Int J Clin Pharmacol Ther
15308589	Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. (2004 Dec)	Fujieda M	Carcinogenesis
20136358	New CYP2A6 gene deletion and conversion variants in a population of Black African descent. (2010 Feb)	Mwenifumbo JC	Pharmacogenomics
28472521	The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings. (2018 Mar 6)	Saccone NL	Nicotine Tob Res
25052864	Comparison of secondhand smoke exposure measures during pregnancy in the development of a clinical prediction model for small-for-gestational-age among non-smoking Chinese pregnant women. (2015 Oct)	Xie C	Tob Control
17037346	[The relationship between smoking behavior in young people and CYP2A6 gene polymorphisms, between them and personality traits assessed by NEO-FFI]. (2006 Aug)	Waga C	Nihon Arukoru Yakubutsu Igakkai Zasshi
25526961	Genetic influence of dopamine receptor, dopamine transporter, and nicotine metabolism on smoking cessation and nicotine dependence in a Japanese population. (2014 Dec 20)	Ohmoto M	BMC Genet
18360915	Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. (2008 May)	Mwenifumbo JC	Hum Mutat
22706231	CYP2A6: genetics, structure, regulation, and function. (2012 May 5)	Raunio H	Drug Metabol Drug Interact
10999944	Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. (2000 Oct)	Rao Y	Mol Pharmacol
12832682	Association of CYP2A6 deletion polymorphism with smoking habit and development of pulmonary emphysema. (2003 Jul)	Minematsu N	Thorax
26014804	Nicotine metabolite ratio (3-hydroxycotinine/cotinine) in plasma and urine by different analytical methods and laboratories: implications for clinical implementation. (2015 Aug)	Tanner JA	Cancer Epidemiol Biomarkers Prev
26757861	[Association between genotype and allele frequencies of CYP2A6*12 and rs16969968 in CHRNA5 variants with smoking and body mass index in young subjects from Northeast Mexico]. (2015 Nov)	Borrego-Soto G	Rev Med Chil
24260284	CYP2B6 non-coding variation associated with smoking cessation is also associated with differences in allelic expression, splicing, and nicotine metabolism independent of common amino-acid changes. (2013)	Bloom AJ	PLoS One
27613936	High Prevalence of Smoking in the Roma Population Seems to Have No Genetic Background. (2016 Dec)	Fiatal S	Nicotine Tob Res
17979512	Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. (2007 Oct)	Mwenifumbo JC	Pharmacogenomics
16485141	Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. (2006 Mar)	Siu EC	Psychopharmacology (Berl)
17671098	CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. (2007 Nov)	Zhang X	J Pharmacol Exp Ther
16678549	Female sex and oral contraceptive use accelerate nicotine metabolism. (2006 May)	Benowitz NL	Clin Pharmacol Ther
19012698	Cigarette smoking and glutathione S-transferase M1 polymorphism associated with risk for uterine cervical cancer. (2008 Dec)	Nishino K	J Obstet Gynaecol Res
22046326	'Smoking genes': a genetic association study. (2011)	Verde Z	PLoS One
20719908	Carbamazepine but not valproate induces CYP2A6 activity in smokers with mental illness. (2010 Oct)	Williams JM	Cancer Epidemiol Biomarkers Prev
11805739	Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. (2002 Feb)	Tyndale RF	Ther Drug Monit
19040121	Detection of cytochrome P450-2A6, -3A5 and -4B1 with real-time polymerase chain reaction in prostate tissue. (2008 Sep-Oct)	Zencir S	Z Naturforsch C
27599351	Application of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic profile of smokers in the real-life setting. (2016 Nov 30)	Fogli S	J Pharm Biomed Anal
16720336	Smoking cessation program and CYP2A6 polymorphism. (2006 Sep 1)	Ozaki S	Front Biosci
19184652	Molecular genetics of nicotine metabolism. (2009)	Mwenifumbo JC	Handb Exp Pharmacol
7788860	Expression of cytochrome P450 and microsomal epoxide hydrolase in cervical and oral epithelial cells immortalized by human papillomavirus type 16 E6/E7 genes. (1995 Jun)	Farin FM	Carcinogenesis
28921760	Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences. (2018 Mar)	Chenoweth MJ	Addiction
21791872	Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan. (2011)	Tamaki Y	Drug Metab Pharmacokinet
22938167	Nicotine intake and smoking topography in smokers with bipolar disorder. (2012 Sep)	Williams JM	Bipolar Disord
29232328	Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism. (2018 Jan)	Tanner JA	Pharmacogenet Genomics
15225612	Novel human CYP2A6 alleles confound gene deletion analysis. (2004 Jul 2)	Nakajima M	FEBS Lett
16758265	Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. (2006 Jun)	Al Koudsi N	Eur J Clin Pharmacol
26060595	CYP2A6 Polymorphisms May Strengthen Individualized Treatment for Nicotine Dependence. (2015)	Akrodou YM	Scientifica (Cairo)
12214673	Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP. (2002 Aug)	Kamataki T	Drug Metab Rev
25872594	Expression of CYP2E1 and CYP2U1 proteins in amygdala and prefrontal cortex: influence of alcoholism and smoking. (2015 May)	Toselli F	Alcohol Clin Exp Res
19279561	Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. (2009 Jun)	Ho MK	Clin Pharmacol Ther
19643819	Interaction between cytochrome P450 1A2 genetic polymorphism and cigarette smoking on the risk of hepatocellular carcinoma in a Japanese population. (2009 Oct)	Imaizumi T	Carcinogenesis
24651583	Genetic polymorphisms in metabolizing enzymes modifying the association between smoking and inflammatory bowel diseases. (2014 May)	Ananthakrishnan AN	Inflamm Bowel Dis
17173682	Etiological study of esophageal squamous cell carcinoma in an endemic region: a population-based case control study in Huaian, China. (2006 Dec 15)	Wang Z	BMC Cancer
21473878	Metabolic effects of CYP2A6 and CYP2A13 on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced gene mutation--a mammalian cell-based mutagenesis approach. (2011 Jun 1)	Chiang HC	Toxicol Appl Pharmacol
23049750	Haplotypes with copy number and single nucleotide polymorphisms in CYP2A6 locus are associated with smoking quantity in a Japanese population. (2012)	Kumasaka N	PLoS One
23027621	Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. (2013 Jan)	Zhu AZ	Carcinogenesis
27488534	Novel Association of Genetic Markers Affecting CYP2A6 Activity and Lung Cancer Risk. (2016 Oct 1)	Patel YM	Cancer Res
19082995	CYP2A6 genotypes and coumarin-oxidation phenotypes in a Thai population and their relationship to tobacco smoking. (2009 Apr)	Mahavorasirikul W	Eur J Clin Pharmacol
25655887	Pharmacogenetics of nicotine and associated smoking behaviors. (2015)	Tanner JA	Curr Top Behav Neurosci
21420395	Direct genotyping of Cytochrome P450 2A6 whole gene deletion from human blood samples by the SmartAmp method. (2011 Jun 11)	Azuma K	Clin Chim Acta
17206525	Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application. (2007 Feb)	Levi M	J Pharmacokinet Pharmacodyn
18216723	A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. (2008 Jan)	Ho MK	Pharmacogenet Genomics
21597399	The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. (2011 Jul)	Bloom J	Pharmacogenet Genomics
23591849	Pilot study of CYP2B6 genetic variation to explore the contribution of nitrosamine activation to lung carcinogenesis. (2013 Apr 16)	Wassenaar CA	Int J Mol Sci
21964962	Interaction between heavy smoking and CYP2A6 genotypes on type 2 diabetes and its possible pathways. (2011 Dec)	Liu T	Eur J Endocrinol
28032407	CYP2A6 metabolism in the development of smoking behaviors in young adults. (2018 Jan)	Olfson E	Addict Biol
17035386	CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. (2006 Oct)	Malaiyandi V	Cancer Epidemiol Biomarkers Prev
27106177	Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products. (2016 Nov)	Anderson GD	Clin Pharmacokinet
29627689	Slower nicotine metabolism among postmenopausal Polish smokers. (2017 Nov 22)	Kosmider L	Pharmacol Rep
14644339	Mechanisms of esophageal cancer development in Brazilians. (2003 Nov)	Ribeiro Pinto LF	Mutat Res
22217675	Association between daily cigarette consumption and hypertension moderated by CYP2A6 genotypes in Chinese male current smokers. (2013 Jan)	Liu T	J Hum Hypertens
29788791	Nicotine metabolite ratio and smoking outcomes using nicotine replacement therapy and varenicline among smokers with and without psychiatric illness. (2018 May 1)	Clyde M	J Psychopharmacol
16372023	Ethnic differences in nicotine metabolic rate among New Zealanders. (2005 Dec 16)	Lea R	N Z Med J
27754415	Effect of Genetic Polymorphisms and Long-Term Tobacco Exposure on the Risk of Breast Cancer. (2016 Oct 14)	Verde Z	Int J Mol Sci
18666753	Genetic and environmental influences on therapeutic and toxicity outcomes: studies with CYP2A6. (2006 Sep)	Satarug S	Curr Clin Pharmacol
16272956	CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents. (2005 Dec)	Huang S	Pharmacogenet Genomics
27035242	Disposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activity. (2016 Jul)	Benowitz NL	Pharmacogenet Genomics
14577978	Nicotine metabolite ratio as a predictor of cigarette consumption. (2003 Oct)	Benowitz NL	Nicotine Tob Res
10911933	Mimicking gene defects to treat drug dependence. (2000)	Sellers EM	Ann N Y Acad Sci
16086027	Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. (2005 Sep)	Yano JK	Nat Struct Mol Biol
22160797	Relationship between amounts of daily cigarette consumption and abdominal obesity moderated by CYP2A6 genotypes in Chinese male current smokers. (2012 Apr)	Liu T	Ann Behav Med
15534625	CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians. (2005)	Vasconcelos GM	Pharmacogenomics J
22486895	Inhibition and inactivation of cytochrome P450 2A6 and cytochrome P450 2A13 by menthofuran, beta-nicotyrine and menthol. (2012 May 30)	Kramlinger VM	Chem Biol Interact
11393269	Determination of coumarin metabolism in Turkish population. (2001 Apr)	Cok I	Hum Exp Toxicol
21919071	Urinary biomarkers for secondhand smoke. (2011)	Ino T	J Clin Lab Anal
20155256	In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population. (2010 Jun)	Djordjevic N	Eur J Clin Pharmacol
23936477	Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake. (2013)	Zhu AZ	PLoS One
12504349	Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour. (2003 Feb 1)	Tricker AR	Toxicology
24380444	High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population. (2014 Jul)	Aklillu E	OMICS
25862079	The allele frequency of CYP2A6*4 in four ethnic groups of China. (2015 Jun)	Pang C	Exp Mol Pathol
27113016	Genome-Wide Association of the Laboratory-Based Nicotine Metabolite Ratio in Three Ancestries. (2016 Sep)	Baurley JW	Nicotine Tob Res
21765098	Combined analysis of CHRNA5, CHRNA3 and CYP2A6 in relation to adolescent smoking behaviour. (2011 Jul)	Rodriguez S	J Psychopharmacol
21205058	Associations of CYP2A6 genotype with smoking behaviors in southern China. (2011 May)	Liu T	Addiction
27338962	Genetics of Substance Use Disorders. (2016 Jul)	Yu C	Child Adolesc Psychiatr Clin N Am
11961061	Accelerated metabolism of nicotine and cotinine in pregnant smokers. (2002 May)	Dempsey D	J Pharmacol Exp Ther
20177288	Pharmacogenomics of maternal tobacco use: metabolic gene polymorphisms and risk of adverse pregnancy outcomes. (2010 Mar)	Aagaard-Tillery K	Obstet Gynecol
15544431	Cigarette smoking, metabolic activation and carcinogenesis. (2004 Oct)	Nishikawa A	Curr Drug Metab
15203795	A meta-analytic review of the CYP2A6 genotype and smoking behavior. (2004 Apr)	Carter B	Nicotine Tob Res
15370155	The genetic basis for smoking behavior: a systematic review and meta-analysis. (2004 Aug)	Munafo M	Nicotine Tob Res
25416559	CYP2A6 reduced activity gene variants confer reduction in lung cancer risk in African American smokers--findings from two independent populations. (2015 Jan)	Wassenaar CA	Carcinogenesis
26818358	Genetic determinants of CYP2A6 activity across racial/ethnic groups with different risks of lung cancer and effect on their smoking intensity. (2016 Mar)	Park SL	Carcinogenesis
23178447	Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population. (2013 Feb 1)	Islam MS	Clin Chim Acta
12223434	Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. (2002 Sep)	Ariyoshi N	Cancer Epidemiol Biomarkers Prev
28432340	Phenome-wide association study for CYP2A6 alleles: rs113288603 is associated with hearing loss symptoms in elderly smokers. (2017 Apr 21)	Polimanti R	Sci Rep
11159795	Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. (2001 Feb)	Oscarson M	Drug Metab Dispos
23933006	Good relationship between saliva cotinine kinetics and plasma cotinine kinetics after smoking one cigarette. (2013 Nov)	Yuki D	Regul Toxicol Pharmacol
23462429	CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers. (2013 Apr)	Chenoweth MJ	Pharmacogenet Genomics
22850738	Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans. (2013)	Djordjevic N	Drug Metab Pharmacokinet
25012994	Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers. (2014 Sep)	Chenoweth MJ	Cancer Epidemiol Biomarkers Prev
18188752	Interactions between genotype and retrospective ADHD symptoms predict lifetime smoking risk in a sample of young adults. (2008 Jan)	McClernon FJ	Nicotine Tob Res
24033696	Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). (2014 Jan)	Chen LS	Addiction
29158210	Longitudinal Influence of Pregnancy on Nicotine Metabolic Pathways. (2018 Feb)	Taghavi T	J Pharmacol Exp Ther
24448396	Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption. (2014 Mar)	Chenoweth MJ	Pharmacogenet Genomics
26648056	Common and Distinct Interactions of Chemical Inhibitors with Cytochrome P450 CYP1A2, CYP2A6 and CYP2B6 Enzymes. (2016)	Raunio H	Drug Metab Lett
25857233	Inhibition effects of Vernonia cinerea active compounds against cytochrome P450 2A6 and human monoamine oxidases, possible targets for reduction of tobacco dependence. (2015 Apr)	Prasopthum A	Drug Metab Pharmacokinet
19537956	CYP1A1 genotype modifies the impact of smoking on effectiveness of HAART among women. (2009 Jun)	Feldman DN	AIDS Educ Prev
26069034	The Nicotine Metabolite Ratio is Associated With Early Smoking Abstinence Even After Controlling for Factors That Influence the Nicotine Metabolite Ratio. (2016 Apr)	Chenoweth MJ	Nicotine Tob Res
21161757	Neural markers of genetic vulnerability to drug addiction. (2010)	Muller DJ	Curr Top Behav Neurosci
25532948	Genotyping of wild-type cytochrome P450 2A6 and whole-gene deletion using human blood samples and a multiplex real-time polymerase chain reaction method with dual-labeled probes. (2015 Feb 20)	Shimizu M	Clin Chim Acta
29568101	CYP2A6 is associated with obesity: studies in human samples and a high fat diet mouse model. (2018 Feb 20)	Wang K	Int J Obes (Lond)
11764938	Lack of correlation between CYP2A6 genotype and smoking habits. (2001)	Schulz TG	Adv Exp Med Biol
28542511	Association of CYP2A6 activity with lung cancer incidence in smokers: The multiethnic cohort study. (2017)	Park SL	PLoS One
21266057	Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data. (2011 Jan 25)	Cox LS	Trials
24163286	Influence of CYP2A6*4 genotypes on maternal serum cotinine among Chinese nonsmoking pregnant women. (2014 Apr)	Xie C	Nicotine Tob Res
25446842	Single tube genotyping of CYP2A6 gene deletion based on copy number determination by quantitative real-time PCR. (2014 Dec)	Liu JH	Exp Mol Pathol
28884473	Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. (2017 Sep 8)	Schuit E	Cochrane Database Syst Rev
11725533	Lack of association between smoking and CYP2A6 gene polymorphisms in A Japanese population. (2001 Oct)	Zhang X	Nihon Arukoru Yakubutsu Igakkai Zasshi
22342802	Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI. (2012 May 1)	Tang DW	Neuroimage
10889542	CYP2A6 genotype and smoking. (2000 Jul)	Tiihonen J	Mol Psychiatry
28101244	Celery extract inhibits mouse CYP2A5 and human CYP2A6 activities via different mechanisms. (2016 Dec)	Deng X	Oncol Lett
21254355	Smoking, the xenobiotic pathway, and clubfoot. (2011 Jan)	Sommer A	Birth Defects Res A Clin Mol Teratol
11134671	Polymorphisms in genes involved in neurotransmission in relation to smoking. (2000 Dec 27)	Arinami T	Eur J Pharmacol
18065502	Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. (2008 Mar)	Siu EC	J Pharmacol Exp Ther
22290489	Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. (2012 Jan 31)	Gold AB	Hum Genet
15734728	Metabolism and disposition kinetics of nicotine. (2005 Mar)	Hukkanen J	Pharmacol Rev
15388242	Effects of cigarette smoking and exposure to cadmium and lead on phenotypic variability of hepatic CYP2A6 and renal function biomarkers in men. (2004 Nov 15)	Satarug S	Toxicology
22451501	Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6. (2012 Jul 1)	Bloom AJ	Hum Mol Genet
25744963	CYP2A6 Longitudinal Effects in Young Smokers. (2016 Feb)	Cannon DS	Nicotine Tob Res
26873401	Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population. (2016 May)	Sawada G	Gastroenterology
11353760	Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. (2001 Jun)	Zhang W	Drug Metab Dispos
19959692	Utility and relationships of biomarkers of smoking in African-American light smokers. (2009 Dec)	Ho MK	Cancer Epidemiol Biomarkers Prev
25220663	Smilax China root extract detoxifies nicotine by reducing reactive oxygen species and inducing CYP2A6. (2014 Oct)	Kim KM	J Food Sci
19702528	Structure, function, regulation and polymorphism of human cytochrome P450 2A6. (2009 Sep)	Di YM	Curr Drug Metab
18976031	CYP2A6 allele frequencies in an Iranian population. (2008 Nov)	Emamghoreishi M	Arch Iran Med
16176798	Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk. (2005 Dec 9)	Kamataki T	Biochem Biophys Res Commun
16452582	Limitation of cigarette consumption by CYP2A64, 7 and *9 polymorphisms. (2006 Feb)	Minematsu N	Eur Respir J
11259349	Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. (2001 Apr)	Tyndale RF	Drug Metab Dispos
23528144	CYP2A6 genotype and smoking behavior in current smokers screened for lung cancer. (2013 May)	Styn MA	Subst Use Misuse
25879453	Effect of mild-to-moderate smoking on viral load, cytokines, oxidative stress, and cytochrome P450 enzymes in HIV-infected individuals. (2015)	Ande A	PLoS One
15735609	Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. (2005 Mar)	Malaiyandi V	Clin Pharmacol Ther
24527722	Electrochemical detection of human cytochrome P450 2A6 inhibition: a step toward reducing dependence on smoking. (2014 Mar 4)	Castrignano S	Anal Chem
24192532	The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans. (2013 Dec)	Bloom AJ	Pharmacogenet Genomics
17221922	In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. (2007 Feb)	Begas E	Biomed Chromatogr
17130279	The role of CYP2A6 in the emergence of nicotine dependence in adolescents. (2007 Jan)	Audrain-McGovern J	Pediatrics
11684323	Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method. (2001 Nov 30)	Paschke T	Toxicology
10668854	Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. (2000 Jan)	Nakajima M	Clin Pharmacol Ther
26100465	Electronic cigarettes: The nicotyrine hypothesis. (2015 Sep)	Abramovitz A	Med Hypotheses
26283763	Deep Sequencing of Three Loci Implicated in Large-Scale Genome-Wide Association Study Smoking Meta-Analyses. (2016 May)	Clark SL	Nicotine Tob Res
18041664	Smoking behavior and related cancers: the role of CYP2A6 polymorphisms. (2007 Dec)	Nakajima M	Curr Opin Mol Ther
27865452	CYP2A6 Genetic Variation Alters Striatal-Cingulate Circuits, Network Hubs, and Executive Processing in Smokers. (2017 Apr 1)	Li S	Biol Psychiatry
17267622	A novel duplication type of CYP2A6 gene in African-American population. (2007 Apr)	Fukami T	Drug Metab Dispos
23692359	CHRNA5-A3-B4 genetic variants alter nicotine intake and interact with tobacco use to influence body weight in Alaska Native tobacco users. (2013 Oct)	Zhu AZ	Addiction
11241319	Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. (2001 Mar 20)	Tan W	Int J Cancer
18942282	Smoking risk and the likelihood of quitting among African-American female light and heavy smokers. (2008 Oct)	Fernander A	J Natl Med Assoc
22080838	A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. (2012 Feb 15)	Cho MH	Hum Mol Genet
17036930	CYP2A6 polymorphism reveals differences in Japan and the existence of a specific variant in Ovambo and Turk populations. (2006 Apr)	Takeshita H	Hum Biol
9653923	Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography. (1998 May 8)	Krul C	J Chromatogr B Biomed Sci Appl
16141602	Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. (2005 Aug)	Nakajima M	Drug Metab Pharmacokinet
23902929	Synthetic models related to methoxalen and menthofuran-cytochrome P450 (CYP) 2A6 interactions. benzofuran and coumarin derivatives as potent and selective inhibitors of CYP2A6. (2013)	Yamaguchi Y	Chem Pharm Bull (Tokyo)
21747048	Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. (2011 Sep 7)	Wassenaar CA	J Natl Cancer Inst
16378601	3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression. (2006 Feb 10)	Wang J	Biochem Biophys Res Commun
17934923	CYP2A6 gene polymorphism and personality traits for NEO-FFI on the smoking behavior of youths. (2007)	Waga C	Drug Chem Toxicol
14757175	Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. (2004 Feb 15)	Denton TT	Biochem Pharmacol
28994497	Effects of Vernonia cinerea Compounds on Drug-metabolizing Cytochrome P450s in Human Liver Microsomes. (2017 Dec)	Pouyfung P	Phytother Res
14981342	Whole deletion of CYP2A6 gene (CYP2A6AST;4C) and smoking behavior. (2004)	Iwahashi K	Neuropsychobiology
10093988	Genetic variation of CYP2A6, smoking, and risk of cancer. (1999 Mar 13)	London SJ	Lancet
17161559	Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. (2007 Jun 15)	Mwenifumbo JC	Drug Alcohol Depend
28734893	Genetic polymorphisms in CYP2A6 are associated with a risk of cigarette smoking and predispose to smoking at younger ages. (2017 Sep 10)	Perez-Rubio G	Gene
12362322	[Researches on the polymorphism of cytochrome P450 2A6]. (2002 Oct)	Tong Z	Zhonghua Yi Xue Yi Chuan Xue Za Zhi
29048184	Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapy. (2017 Oct)	Glatard A	Exp Clin Psychopharmacol
9806171	Measurement of cytochrome P450 2A6 and 2E1 gene expression in primary human bronchial epithelial cells. (1998 Oct)	Crawford EL	Carcinogenesis
27974382	Functional Characterization of 34 CYP2A6 Allelic Variants by Assessment of Nicotine C-Oxidation and Coumarin 7-Hydroxylation Activities. (2017 Mar)	Hosono H	Drug Metab Dispos
16402086	CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation. (2006 Mar-Apr)	Kubota T	Pharmacogenomics J
10217419	Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. (1999 Apr 1)	Oscarson M	FEBS Lett
11197315	Effect of cigarette smoking on coumarin metabolism in humans. (2000 Nov)	Poland RE	Nicotine Tob Res
25845234	[Association of the nicotine and cigarette smoke toxicants metabolic (CHRNA3/5, CYP2A6, NQO1) and DNA repair genes (XRCC1, XRCC3, XPC, XPA) with chronic obstructive pulmonary disease]. (2014 Nov-Dec)	Korytina GF	Mol Biol (Mosk)
23203414	Association between CYP2A6 genetic polymorphisms and lung cancer: a meta-analysis of case-control studies. (2013 Mar)	Liu T	Environ Mol Mutagen
10448083	The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. (1999 Aug 19)	Kitagawa K	Biochem Biophys Res Commun
16891249	CYP2A6 polymorphisms in Malays, Chinese and Indians. (2006 Aug)	Nurfadhlina M	Xenobiotica
28253085	Water pipe (Shisha, Hookah, Arghile) Smoking and Secondhand Tobacco Smoke Effects on CYP1A2 and CYP2A6 Phenotypes as Measured by Caffeine Urine Test. (2017 Mar)	Yilmaz SG	OMICS
21685187	Genome-wide association study of smoking behaviours in patients with COPD. (2011 Oct)	Siedlinski M	Thorax
18715882	CYP2A6 activity in a healthy Spanish population: effect of age, sex, smoking, and oral contraceptives. (2008 May)	Sinues B	Hum Exp Toxicol
26407342	A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism. (2015)	Loukola A	PLoS Genet
24651674	Contribution of environment and genetics to pancreatic cancer susceptibility. (2014)	Hocevar BA	PLoS One
26541911	CYP2A6 Effects on Subjective Reactions to Initial Smoking Attempt. (2016 May)	Cannon DS	Nicotine Tob Res
24163739	Genetic susceptibility to lung cancer and co-morbidities. (2013 Oct)	Yang IA	J Thorac Dis
21149643	Genetic polymorphism and toxicology--with emphasis on cytochrome p450. (2011 Mar)	Johansson I	Toxicol Sci
23933970	Genetic and pharmacokinetic determinants of response to transdermal nicotine in white, black, and Asian nonsmokers. (2013 Dec)	Dempsey DA	Clin Pharmacol Ther
11975862	Gender differences in tobacco smoking: higher relative exposure to smoke than nicotine in women. (2002 Mar)	Zeman MV	J Womens Health Gend Based Med
16765148	Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. (2006 Jun)	Lerman C	Clin Pharmacol Ther
11281276	The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. (2000 Sep)	Gu DF	Ann Hum Genet
12749606	Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults. (2003 May)	Ando M	J Epidemiol
12024803	Effects of whole deletion of CYP2A6 on nicotine metabolism in humans. (2002 May)	Zhang X	Drug Chem Toxicol
19251454	5HTT polymorphisms are associated with job stress in Japanese workers. (2009 Apr)	Katsuyama H	Leg Med (Tokyo)
15658857	Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. (2005 Jan 27)	Rahnasto M	J Med Chem
11401907	Individual differences in urinary cotinine levels in Japanese smokers: relation to genetic polymorphism of drug-metabolizing enzymes. (2001 Jun)	Yang M	Cancer Epidemiol Biomarkers Prev
12115524	Effects of cytochrome P450 (CYP) 2A6 gene deletion and CYP2E1 genotypes on gastric adenocarcinoma. (2002 Aug 1)	Tsukino H	Int J Cancer
8619884	Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. (1996 Feb 23)	Hakkola J	Biochem Pharmacol
15527659	Pharmacogenetics of nicotine metabolism in twins: methods and procedures. (2004 Oct)	Swan GE	Twin Res
19793020	A review of smoking behavior and smokers evidence (chemical modification, inducing nicotine metabolism, and individual variations by genotype: dopaminergic function and personality traits). (2009)	Iwahashi K	Drug Chem Toxicol
22019468	Identification of novel CYP2A6 inhibitors by virtual screening. (2011 Dec 1)	Rahnasto MK	Bioorg Med Chem
10544257	Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. (1999 Oct 29)	Oscarson M	FEBS Lett
12487152	Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6. (2002 Nov)	Nakajima M	Drug Metab Rev
28472995	Interaction between cytochrome P450 2A6 and Catechol-O-Methyltransferase genes and their association with smoking risk in young men. (2017 May 4)	Ou WC	Behav Brain Funct
25281486	A DRD1 polymorphism predisposes to lung cancer among those exposed to secondhand smoke during childhood. (2014 Dec)	Robles AI	Cancer Prev Res (Phila)
17021260	Inhibition of nicotine metabolism by methoxysalen: Pharmacokinetic and pharmacological studies in mice. (2007 Jan)	Damaj MI	J Pharmacol Exp Ther
12406643	CYP2A6 genetic variation and potential consequences. (2002 Nov 18)	Xu C	Adv Drug Deliv Rev
16815959	CYP2A13 in human respiratory tissues and lung cancers: an immunohistochemical study with a new peptide-specific antibody. (2006 Oct)	Zhu LR	Drug Metab Dispos
15735610	Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. (2005 Mar)	Hukkanen J	Clin Pharmacol Ther
17485391	Increased cytochrome P450 and aryl hydrocarbon receptor in bronchial epithelium of heavy smokers with non-small cell lung carcinoma carries a poor prognosis. (2007 May 1)	Oyama T	Front Biosci
19029401	Nicotine metabolism in three ethnic/racial groups with different risks of lung cancer. (2008 Dec)	Derby KS	Cancer Epidemiol Biomarkers Prev
26095139	Gene expression profiling of cytochromes P450, ABC transporters and their principal transcription factors in the amygdala and prefrontal cortex of alcoholics, smokers and drug-free controls by qRT-PCR. (2015)	Toselli F	Xenobiotica
21443033	Relationship between CYP2A6 genetic polymorphism, as a marker of nicotine metabolism, and ulcerative colitis. (2011 Feb)	Altarescu G	Isr Med Assoc J
11768189	A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption. (1999)	Tyndale RF	Nicotine Tob Res
19415821	Gene-gene interactions of CYP2A6 and MAOA polymorphisms on smoking behavior in Chinese male population. (2009 May)	Tang X	Pharmacogenet Genomics